OXFORD, United Kingdom, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd ('Evox'), a leading exosome therapeutics company, today announced the publication in Nature Communications of...
OXFORD, United Kingdom, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd ('Evox'), a leading exosome therapeutics company, today announced a research collaboration and option agreement with...
OXFORD, United Kingdom, May 17, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd , a leading exosome therapeutics company, today announced that the Company has been granted...
OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, will present data at two upcoming international...
OXFORD, United Kingdom, May 26, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announced advances in exosome engineering,...
OXFORD, United Kingdom, May 24, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, will participate in the 2022 Jefferies Healthcare...
OXFORD, United Kingdom, May 09, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announced two oral presentations at the...
OXFORD, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announces the appointment of Peter Jones as Vice...
After a busy 2020, Evox Therapeutics is topping up its coffers to take its work to the next level. The U.K.-based biotech raised £69.2 million ($95.4 million) from the likes of OrbiMed and GV to advance a pipeline of exosome-based treatments into the clinic and further develop the technology that underpins them.
Oxford-based biotech company Evox Therapeutics has completed a Series C financing round, announcing that it has raised £69.2m ($95.4m) following ‘high demand’ from existing and new investors.